NIAID’s VRC, S. Africa’s Afrigen Kick Off Vaccine-Sharing Efforts

Friday, Aug. 11, 2023 Kicking Off Vaccine-Sharing Efforts Caption: Scientists from NIAID and Afrigen Biologics and Vaccines (South Africa) during a training session in Frederick, Maryland. (NIAID) Seven scientists from Afrigen Biologics and Vaccines in South Africa recently spent two weeks in Maryland training with NIAID Vaccine Research Center counterparts on how to make mRNA vaccines. The visit was a key milestone in an ongoing collaboration to share knowledge, expertise, and data to expedite mRNA vaccine production globally. The collaboration started in July 2021 to build capacity in low- and middle-income countries to make mRNA vaccines against COVID-19. The project aims to create mRNA vaccines against a list of troubling infectious diseases, such as HIV, tuberculosis, malaria, influenza, cancer-associated viruses and more. The mRNA vaccine platform works by delivering a piece of genetic material to cells that instructs the body to make a protein fragment resembling one from a target pathogen (such as a virus). The immune system then recognizes and remembers the fragment, enabling it to mount a strong response if the body is later exposed to that pathogen. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107